Researchers: Marie Knufinke, Michael R MacArthur, Collin Y Ewald, Sarah J Mitchell
With an increasing aging population, the burden of age-related diseases magnifies. To alleviate this burden, geroprotection has been an area of intense research focus with the development of pharmacological interventions that target lifespan and/or healthspan. However, there are often sex differences, with compounds mostly tested in male animals. Given the importance of considering both sexes in preclinical research, this neglects potential benefits for the female population, as interventions tested in both sexes often show clear sexual dimorphisms in their biological responses. To further understand the prevalence of sex differences in pharmacological geroprotective intervention studies, we performed a systematic review of the literature according to the PRISMA guidelines. Seventy-two studies met our inclusion criteria and were classified into one of five subclasses: FDA-repurposed drugs, novel small molecules, probiotics, traditional Chinese medicine, and antioxidants, vitamins, or other dietary supplements. Interventions were analyzed for their effects on median and maximal lifespan and healthspan markers, including frailty, muscle function and coordination, cognitive function and learning, metabolism, and cancer. With our systematic review, we found that twenty-two out of sixty-four compounds tested were able to prolong both lifespan and healthspan measures. Focusing on the use of female and male mice, and on comparing their outcomes, we found that 40% of studies only used male mice or did not clarify the sex. Notably, of the 36% of pharmacologic interventions that did use both male and female mice, 73% of these studies showed sex-specific outcomes on healthspan and/or lifespan. These data highlight the importance of studying both sexes in the search for geroprotectors, as the biology of aging is not the same in male and female mice. Systematic Review Registration: [website], identifier [registration number].
References
- A toolbox for the longitudinal assessment of healthspan in aging mice.
- Sex-specific aging in animals: Perspective and future directions.
- Sex Differences in Inflammation and Muscle Wasting in Aging and Disease.
- Molecular mechanisms of dietary restriction promoting health and longevity.
- Late-life intermittent fasting decreases aging-related frailty and increases renal hydrogen sulfide production in a sexually dimorphic manner.
- Nutrition, longevity and disease: From molecular mechanisms to interventions.
- Interventions to Slow Aging in Humans: Are We Ready?
- Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice.
- Effects of Sex, Strain, and Energy Intake on Hallmarks of Aging in Mice.
- Developing criteria for evaluation of geroprotectors as a key stage toward translation to the clinic.
- Frailty index as a biomarker of lifespan and healthspan: Focus on pharmacological interventions.
- Study of Longitudinal Aging in Mice: Presentation of Experimental Techniques.
- Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span.
- Longevity interventions temporally scale healthspan in Caenorhabditis elegans.
- Evaluation of resveratrol, green tea extract, curcumin, oxaloacetic acid, and medium-chain triglyceride oil on life span of genetically heterogeneous mice.